Development of Vi conjugate – a new generation of typhoid vaccine

@article{Szu2013DevelopmentOV,
  title={Development of Vi conjugate – a new generation of typhoid vaccine},
  author={Shousun Chen Szu},
  journal={Expert Review of Vaccines},
  year={2013},
  volume={12},
  pages={1273 - 1286}
}
  • S. Szu
  • Published 1 November 2013
  • Medicine
  • Expert Review of Vaccines
Typhoid fever remains to be a serious disease burden worldwide with an estimated annual incidence about 20 million. The licensed vaccines showed moderate protections and have multiple deficiencies. Most important of all, none of the licensed typhoid vaccines demonstrated protection for children under 5 years old. These limitations impeded successful implementation of typhoid vaccination programs. To improve immunogenicity Vi was conjugated to rEPA, a recombinant exoprotein A from Pseudomonas… Expand
Comment on: development of Vi conjugate – a new generation of typhoid vaccine
TLDR
The expanded usage of conjugated Vi vaccines in areas with frequent circulation of Vi-negative isolates could aid in selection and dissemination of the Vi- negative strains in the community. Expand
Preventing invasive salmonellosis in children through vaccination
TLDR
The main aim of this paper is to discuss the efficacy of available EF vaccines in children and to highlight novel vaccination possibilities against EF and non-typhoid invasive salmonelloses to significantly reduce incidence rates of EF in younger children. Expand
Novel Vi conjugate vaccines against typhoid
Typhoid fever remains a major public health concern in low-income countries affecting millions of people each year. Research on effective vaccines against Salmonella Typhi has been directed towardExpand
Improved Vaccine Design and Delivery as Part of an Integrated Approach toMeet the Public Health Challenge of Typhoid Fever in Developing Countries
TLDR
The key virulence factors of S. typhi that are associated with antibiotic resistance are highlighted and the need to introduce widespread public vaccination programs to help combat typhoid fever worldwide is considered. Expand
Immunogenicity and Safety of Typhoid Conjugate Vaccine in Healthy Indian Subjects: A Randomized, Active-controlled, Comparative Clinical Trial
TLDR
The immunogenicity and safety of test TCV is comparable to already marketed comparator TCV and the most common adverse event was injection-site pain followed by fever in both the groups. Expand
The need & the issues related to new-generation typhoid conjugate vaccines in India
TLDR
The current review provides an update on the existing and upcoming new TCVs along with a detailed discussion on the various issues involved with their clinical use and limitations. Expand
Salmonella Typhi outer membrane protein STIV is a potential candidate for vaccine development against typhoid and paratyphoid fever.
  • Sayan Das, Rimi Chowdhury, Ananda Pal, Keinosuke Okamoto, Santasabuj Das
  • Medicine
  • Immunobiology
  • 2019
TLDR
It is shown that recombinant, S. Typhi outer membrane protein STIV (rSTIV) is immunogenic in mice and elicits high serum titers of different immunoglobulin subtypes, which underscores the potential of rSTIV as a novel vaccine candidate for enteric fever. Expand
First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
TLDR
It is concluded that reductive amination is the superior method to prepare the S. Typhi OSP glycoconjugate and rEPA was a better carrier protein than HSA, and seems to be efficacious typhoid vaccines candidate. Expand
Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
TLDR
This work explored the possibility of generating a bivalent vaccine against Plasmodium falciparum malaria and typhoid fever by conjugating Vi polysaccharide, an approved antigen in typhoid vaccine, to Pfs25, a malaria transmission blocking vaccine antigen in clinical trials. Expand
Typhoid vaccines. Historical aspects of typhoid vaccine development, and currently available products
Typhoid fever is an acute infectious disease caused by Salmonella enterica subsp. enterica serovar Typhi (S. Typhi), which is still extremely common in endemic low- and middle-income countries ofExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines
TLDR
Vi-rEPA was safe, induced protective anti-Vi levels, and was compatible with EPI vaccines, and it can be used in infants. Expand
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
TLDR
The antibody responses and the efficacy suggest that the Vi-rEPA conjugate typhoid vaccine should be at least as protective in persons who are more than five years old. Expand
Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
To the Editor: The limitations of the three licensed typhoid vaccines that precluded their use in children younger than five years old have been overcome by a Vi conjugate vaccine (Vi-rEPA, aExpand
Population impact of Vi capsular polysaccharide vaccine
TLDR
The large-scale use of the new-generation Vi polysaccharide single-dose injectable typhoid vaccine can yield protective benefits to a larger population and can reduce the epidemiologic and economic burden of Typhi in endemic countries. Expand
PROTECTIVE ACTIVITY OF VI CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID FEVER
TLDR
Vi CPS is a safe and effective means of typhoid vaccination and an increase in anti-Vi antibodies occurred, as measured by radioimmunoassay and enzyme-linked immunosorbent assay, at 6 and 12 months post vaccination. Expand
Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults
TLDR
Vi-CRM197 did not elicit safety concerns, was highly immunogenic and is therefore suitable for further clinical testing in endemic populations of South Asia. Expand
Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
TLDR
The locally produced Vi polysaccharide vaccine showed levels of protective efficacy similar to those for Vi vaccine produced in industrial countries, and did not seem to alter efficacy significantly in China. Expand
A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.
TLDR
This preparation of a human IgG anti-Vi standard is suitable for comparison of immune response of Vi conjugate vaccines or for other purposes requiring anti- Vi measurement. Expand
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
TLDR
Under conditions of intense transmission,Ty21a protected against typhoid fever; however, because Ty21a will not protect all individuals, there is a need for additional approaches to prevent the disease. Expand
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.
TLDR
The protective efficacy and immunogenicity of Vi capsular polysaccharide vaccine against typhoid fever was measured 3 years after its administration in a double-blind randomized trial and the estimated protective level is 1 microgram ml-1 suggesting that at a mean age of 9 years, 64% of vaccinates and 40% of controls had protective antibody against Typhoid fever in this endemic area. Expand
...
1
2
3
4
5
...